Literature DB >> 7209417

An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer.

K Trautner, E H Cooper, S Haworth, A M Ward.   

Abstract

Longitudinal and vertical studies on prostatic cancer have confirmed that many forms of oestrogen therapy have a profound effect on the levels of several acute phase reactant proteins (APRP). This action overrides any response of the APRPs to a rising tumour load. However, serum C-Reactive protein and albumin levels appear to be independent of oestrogen control and their respective rise and fall is associated with tumour progression even when the patient is saturated with oestrogens.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7209417     DOI: 10.3109/00365598009179552

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  4 in total

1.  C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older.

Authors:  Brandon L Pierce; Mary L Biggs; Marvalyn DeCambre; Alexander P Reiner; Christopher Li; Annette Fitzpatrick; Christopher S Carlson; Janet L Stanford; Melissa A Austin
Journal:  Cancer Causes Control       Date:  2009-03-08       Impact factor: 2.506

2.  Association between PSA Levels and Biomarkers of Subclinical Systemic Inflammation in Middle-Aged Healthy Men from the General Population.

Authors:  Saad Elzanaty; Babak Rezanezhad; Rasmus Borgquist
Journal:  Curr Urol       Date:  2016-09-20

Review 3.  A review of the application of inflammatory biomarkers in epidemiologic cancer research.

Authors:  Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

4.  Immunological studies of patients with tumours of the prostate and bladder (a retrospective analysis).

Authors:  I Romics; J Fehér; J Horváth
Journal:  Int Urol Nephrol       Date:  1983       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.